Hierarchical true prevalence, risk factors and clinical symptoms of tuberculosis among suspects in Bangladesh

Background The study was aimed to estimate the true prevalence of human tuberculosis (TB); identify risk factors and clinical symptoms of TB; and detect rifampicin (RIF) sensitivity in three study areas of Bangladesh. Methods The cross-sectional study was conducted in three Bangladesh districts during 2018. Potential risk factors, clinical symptoms, and comorbidities were collected from 684 TB suspects. Sputum specimens were examined by LED microscopy. TB hierarchical true prevalence, risk factors and clinical symptoms were estimated and identified using a Bayesian analysis framework. Rifampicin sensitivity of M. tuberculosis (MTB) was detected by GeneXpert MTB/RIF assay. Results The median TB true prevalence was 14.2% (3.8; 34.5). Although overall clustering of prevalence was not found, several DOTS centers were identified with high prevalence (22.3% to 43.7%). Risk factors for TB identified (odds ratio) were age (> 25 to 45 years 2.67 (1.09; 6.99), > 45 to 60 years 3.43 (1.38; 9.19) and individuals in families/neighborhoods where a TB patient(s) has (ve) already been present (12.31 (6.79; 22.60)). Fatigue, night sweat, fever and hemoptysis were identified as important clinical symptoms. Seven of the GeneXpert MTB/RIF positive sputum specimens (65) were resistant to rifampicin. Conclusions About one in every seven TB suspects was affected with TB. A number of the TB patients carry multi drug resistant MTB. Hierarchical true prevalence estimation allowed identifying DOTS centers with high TB burden. Insights from this study will enable more efficient use of DOTScenters-based TB surveillance to end the TB epidemic in Bangladesh by 2035.


Introduction
The cross-sectional study was conducted from January to December 2018 among 114 the TB suspects attending DOTS centers in the Mymensingh, Sirajganj and Dhaka districts 115 of Bangladesh. 116 Sample size calculation and sampling techniques 117 Using the Guilford and Frucher formula ( = 2 2 ) ( Guilford and Frucher, 1973), 118 assuming a prevalence of 50% [p=0.5] (no previous report) among the subpopulation 119 suspect of TB in Bangladesh, the minimum calculated sample size was 600, at a 120 significance level of 5% and with 4% acceptable margin of error. From 8 administrative 121 divisions of Bangladesh we selected 3 divisions randomly. Again, from each selected 122 division we selected one district randomly namely Mymensingh, Sirajganj and Dhaka. 123 From each district 8 DOTS centers were selected randomly i.e. ultimately, we randomly 124 selected 24 DOTS centers from Mymensingh, Sirajganj and Dhaka districts. Finally, a 125 convenience sample of 684 TB suspects attending those DOTS centers were interviewed 126 using pretested, semi-structured case record forms, which included information on 127 symptoms, socio-demographic characteristics and risk factors for TB.

128
Collection of specimens 129 Each TB suspect brought a morning sputum specimen in the plastic container 130 provided by the NTP. After conducting face to face interview another sputum specimen 131 from each TB suspect was collected on the spot.

132
Auramine staining and LED microscopy 133 Thin smear slides were made from the purulent part of the sputum. Auramine-134 rhodamine was used as a fluorescent dye to stain acid-fast bacteria (AFB) and examined . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 under LED microscope on high power (400X). Acid-fast organisms fluoresced bright 136 yellow or orange against a dark background (Tankeshwar, 2015).

138
GeneXpertMTB/RIF assay was performed following the protocol of the 139 manufacturer (Cepheid Inc., Sunnyvale, CA, USA). Sputum specimens were collected in 140 containers provided and treated with sample reagent in a proportion of 2:1 and incubated 141 for 15 minutes at room temperature. Two milliliters reagent treated sample was pipetted 142 into the sample chamber of the Xpert cartridge. The Xpert cartridge was then placed into 143 the GeneXpert instrument system and run. Results were generated after 90 min.  in the tPRiors: 50% mean prevalence, 95% level of confidence that the true value of the 165 mean is greater than the percentile value, the upper limit of the mean as 80.0% at 95% level 166 of confidence, the level of confidence that a certain fraction of the units under study has a 167 prevalence less than the 'percentile.median' as 81.1%, the median value of the defined 168 'psi.percentile' as 82% and the value that the 'percentile.median' does not exceed 90% with 169 95% confidence. The influence of prior information on the posterior true prevalence was . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.18.22269059 doi: medRxiv preprint we used mixed-effect univariable logistic regression models with clinic as a random-effects 177 term, within a Bayesian estimation framework. All candidate explanatory variables were 178 initially screened, one-by-one. Variables with a Bayesian p-value <0.25 were then offered 179 to a full model which was, subsequently reduced by backwards elimination, until only   (Table   212 1). About 60% (50.3; 69.3) of the tested (108) individuals were GeneXpert MTB/RIF assay 213 positive. Among them 89.2% (78.5; 95.2) and 10.8% (4.8; 21.5) were rifampicin sensitive . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 24, 2022. Individuals with fatigue and experiencing night sweats were 4.8(2.6; 9.0) and 8.7 252 (2.5; 31.9) times more likely to be TB positive, respectively. Individuals with hemoptysis 253 and fever had 9.6 (3.7; 25.8) and 9.1 (2.6; 43.3) times higher odds of being TB positive, 254 respectively ( Table 3). Results of the univariable pre-screening are provided as a 255 Supplementary File 6. No multicollinearity was detected among the selected explanatory 256 variables for multivariable regression.

258
Both risk factor and clinical symptoms models converged well (the R-hat values 259 were less than 1.1) and the effective sample sizes were more than the total number of

264
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 24, 2022. suspects was found to be affected by TB and some DOTS centers had a high TB burden. 269 We identified risk factors for TB and clinical symptoms associated with TB positivity.  Age and presence of a TB patient at home or neighborhood were risk factors for TB.

275
The risk of developing TB is high in close family members compared to more distant years) is more vulnerable to TB than the inactive or older age group (Herchline, 2020).

282
Evidence of transmission of TB from animals to humans, which has been reported and 283 could be of major concern in Bangladesh, was not found here. Also, a range of potential

289
We identified fatigue, night sweats, hemoptysis, and fever (but not the presence of a 290 long lasting cough) as clinical symptoms associated with TB occurrence. Hence, patients 291 with fatigue and/or night sweats and/or hemoptysis and/or fever should be rigorously 292 examined for TB even in the absence of coughing. Fever, cough, fatigue, weight loss, chest 293 pain, hemoptysis, difficult breathing, night sweats, and loss of appetite are the common 294 clinical symptoms associated with TB (Banu et al. 2013;Hossain et al. 2015).

295
After adjusting for the sensitivity and specificity of smear microscopy the median 296 true prevalence of TB among tested people was 14.2%. We identified several DOTS 297 centers with high TB prevalence including Fulpur, Trishal, Nanadail, Muktagacha, Fulbaria 298 and Sirajganj Sadar. Although overall no significant clustering was detected, two 299 subdistricts (Fulpur and Trishal) had higher prevalence (43.7% and 43.3%). The 300 autocorrelation of the residuals of the risk factor model was also non-significant, indicating 301 that this model adequately explained the spatial distribution of risk. The existing TB 302 surveillance should prioritize DOTS centers with high prevalence for more efficient TB 303 control programs. The true prevalence of human TB in different DOTS centers will also 304 enable policy planners to allocate resources for TB treatment. Further investigation of 305 subdistricts with high TB prevalence is warranted. We included DOTS centers in 3 306 divisions out of eight and health service has workforce to reach every household in 307 Bangladesh to convey health related information. So, the true prevalence of tuberculosis 308 among TB suspects likely is representative of the whole country.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 24, 2022.

435
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.18.22269059 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10. 1101/2022